In vitro and in vivo Human Metabolism of (S)-[18F]Fluspidine – A Radioligand for Imaging σ1 Receptors With Positron Emission Tomography (PET)
(S)-[18F]fluspidine ((S)-[18F]1) has recently been explored for positron emission tomography (PET) imaging of sigma-1 receptors in humans. In the current report, we have used plasma samples of healthy volunteers to investigate the radiometabolites of (S)-[18F]1 and elucidate their structures with LC-MS/MS. For the latter purpose additional in vitro studies were conducted by incubation of (S)-[18F]1 and (S)-1 with human liver microsomes (HLM). In vitro metabolites were characterized by interpretation of MS/MS fragmentation patterns from collision-induced dissociation or by use of reference compounds. Thereby, structures of corresponding radio-HPLC-detected radiometabolites, both in vitro and in vivo (human), could be identified. By incubation with HLM, mainly debenzylation and hydroxylation occurred, beside further mono- and di-oxygenations. The product hydroxylated at the fluoroethyl side chain was glucuronidated. Plasma samples (10, 20, 30 min p.i., n = 5-6), obtained from human subjects receiving 250–300 MBq (S)-[18F]1 showed 97.2, 95.4, and 91.0% of unchanged radioligand, respectively. In urine samples (90 min p.i.) the fraction of unchanged radioligand was only 2.6% and three major radiometabolites were detected. The one with the highest percentage, also found in plasma, matched the glucuronide formed in vitro. Only a small amount of debenzylated metabolite was detected. In conclusion, our metabolic study, in particular the high fractions of unchanged radioligand in plasma, confirms the suitability of (S)-[18F]1 as PET radioligand for sigma-1 receptor imaging.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.1007/s00216-012-6541-2
- https://doi.org//10.1007/s12010-009-8689-6
- https://doi.org//10.1586/14737175.2015.1023296
- https://doi.org//10.2967/jnumed.116.188052
- https://doi.org//10.1124/dmd.105.006411
- https://doi.org//10.2967/jnumed.114.137562
- https://doi.org//10.1007/s12264-014-1460-6
- https://doi.org//10.1007/s00259-010-1658-z
- https://doi.org//10.1016/j.pharmthera.2010.04.003
- https://doi.org//10.1016/j.bmc.2009.03.060
- https://doi.org//10.1021/jm900909e
- https://doi.org//10.1016/j.bmc.2010.11.013
- https://doi.org//10.1002/cmdc.201300322
- https://doi.org//10.1016/j.tetasy.2013.12.009
SHARE
Usage metrics
![Frontiers in Pharmacology](https://s3-eu-west-1.amazonaws.com/876az-branding-figshare/frontiers/logo.png)